SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to highly positive Phase 3 trial results for its hereditary angioedema therapy, marking a major milestone for in vivo CRISPR gene editing. While many in the community anticipate a potential short squeeze due to high short interest and the significant clinical success, others are warning of a 'sell-the-news' reaction following the stock's recent run-up.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant community excitement as investors anticipate critical clinical trial updates and a high-profile oral presentation at the upcoming Digestive Disease Week (DDW) conference. Supporters are highlighting the company's strong institutional backing and technical progress as key drivers, viewing the current market positioning as a strategic accumulation opportunity ahead of potential upcoming data catalysts.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is trending following a trading halt prompted by the news that its drug tovecimig did not meet the overall survival secondary endpoint in a Phase 2/3 study. The community is actively debating the implications for the company's regulatory path and future BLA filing, with significant skepticism regarding the trial design and statistical outcomes.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors respond to a multi-billion dollar share buyback program and strong subscriber growth fueled by competitive service pricing, which many in the community view as a successful defensive strategy against rivals. Market participants are actively discussing the stock's stability and consistent dividends as a pivot point for defensive positioning while tracking its recent breakout to multi-year highs.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending after a series of positive analyst initiations, including a new Buy rating with a 29 target, alongside excitement for its denifanstat program in both MASH and acne. Investors are actively discussing the stock's potential as a buyout candidate, comparing it to recent industry acquisitions, and are closely monitoring institutional accumulation patterns.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing community attention as traders debate the coin's potential during the annual 'Doge Day' festivities, with sentiment split between long-term holders anticipating a breakout and skeptics focusing on consolidation patterns. The active discussion is driven by retail interest in meme coin volatility and ongoing speculation regarding future adoption or social media catalysts.

RE/MAX Holdings, Inc. engages in the provision of real estate franchise services through its subsidiaries. It operates through the following segments: Real Estate, Mortgage and Marketing Funds. The Real Estate segment consists of the company’s owned and independent global franchising operations under the RE/MAX brand name and technology and data subscription for Gadberry and the First app. The Mortgage segment consists of the firm's mortgage brokerage franchising operations under the Motto Mortgage brand name and mortgage loan processing services and licensed software under the wemlo brand. The Marketing Funds segment is involved in marketing campaigns designed to build and maintain brand awareness and the development and operation of agent marketing technology. The company was founded by David L. Liniger and Gail A. Liniger in 1973 and is headquartered in Denver, CO.

RE/MAX Holdings Inc - Ordinary Shares - Class A

RE/MAX Holdings is currently at the center of market discussions as investors weigh its potential for an acquisition against broader real estate sector challenges. While some in the community are optimistic about a potential takeout and the company's long-term brand value, others remain cautious due to the competitive landscape and ongoing industry consolidation.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is experiencing significant market attention following positive Phase 2a results for its lead candidate ORKA-001 in treating moderate-to-severe plaque psoriasis. Investors are actively discussing the potential for clinical differentiation against established market leaders, while also debating the long-term impact of recent capital-raising activities and the company's ambitious valuation.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven project fueled by active developer engagement, including consistent token airdrops and transparency regarding project milestones. Investors are closely tracking the token's ability to hold its floor following recent highs, with many in the community optimistic about its potential as a multi-day runner while they await upcoming chart integrations.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is attracting significant investor attention following reports that it is collaborating with OpenAI to develop AI-powered smartphone processors, a development seen as a major catalyst for the semiconductor sector. The community is actively discussing the stock's potential as an undervalued AI-at-the-edge play, with many traders debating the long-term impact of this partnership on mobile device innovation versus lingering concerns about handset market headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Schwab Fundamental Emerging Markets Equity ETF (FNDE) a Strong ETF Right Now?

Time for Emerging Markets ETFs?

Emerging markets are surging on a weak dollar, Fed cuts & AI-fueled Chinese tech rally. ETFs like EEM & CQQQ are outpacing the S&P 500 in 2025.

ADR shares of JD.com ($JD) were up 0.3% in after hours trading on Tuesday after the e-commerce reportedly announced it was expanding into food delivery business in China, but retail sentiment appeared cautious.According to a Reuters report, JD.com has begun onboarding catering merchants for its new platform, JD Takeaway. The company posted on its Weixin account, with the message, "Join us now, zero commissions all year round!" The new platform also announced commission-free services until the end of 2025 for those registering before May 1.JD Takeaway plans to offer "comprehensive support for merchants, aiming to promote the healthy and sustainable development of the food delivery industry," said the report.&nbsp;JD Takeaway will enter the highly competitive food delivery sector that has big names such as Meituan and Alibaba’s (BABA) Eleme.Sentiment on Stocktwits appeared cautiously bullish, with some commenters hoping to buy into the dip of recent tariff-fueled volatility in Chinese stocks.<stembedurl>https://stocktwits.com/JustAce/message/603765478</stembedurl><stembedurl>https://stocktwits.com/climbfarmer/message/603727446</stembedurl><stembedurl>https://stocktwits.com/StockNipsDaily/message/603755096</stembedurl> JD was recently put on a "positive catalyst watch” by JP Morgan amid broader optimism among Chinese firms on the back of better-than-expected economic data.JP Morgan maintains an ‘Overweight’ rating with a $50 price target and expects JD's revenue growth to see a better-than-expected boost from trade-in policies, with more resilient margins thanks to investment discipline, Fly.com reported.JP Morgan forecasts JD’s Q4 revenue growth to be about 9.5% year-over-year, beating consensus estimates by 3%, and adjusted net profit projected to grow 13% compared to last year, Investing.com reported. JD.com stock is up 14.7% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com

JD Stock In Focus On Potential Plan To Enter Food Delivery Business: Retail's Cautiously Optimistic

JD Takeaway plans to offer "comprehensive support for merchants, aiming to promote the healthy and sustainable development of the food delivery industry." 

Equity

ADR shares of JD.com ($JD) surged nearly 10% on Friday after the e-commerce company was put on "positive catalyst watch” by JP Morgan amid broader optimism among Chinese firms on the back of better-than-expected economic data, lifting retail sentiment.JP Morgan maintains an ‘Overweight’ rating with a $50 price target, Fly.com reported. According to the firm, JD's revenue growth should see a better-than-expected boost from trade-in policies, with more resilient margins thanks to investment discipline, according to the report.&nbsp;JP Morgan forecasts JD’s Q4 revenue growth to be about 9.5% year-over-year, beating consensus estimates by 3%, and adjusted net profit projected to grow 13% compared to last year, Investing.com reported.China’s economic activity exceeded expectations for the last quarter of 2024 with stimulus measures taking effect, providing a boost to several Chinese stocks.Sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ last week. Message volumes were in the ‘normal’ category.<figure class="image"><img style="aspect-ratio:1314/310;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_01_21_at_2_05_48_PM_4a5b37fc27.png" alt="Screenshot 2025-01-21 at 2.05.48 PM.png" width="1314" height="310"><figcaption>JD sentiment meter and message volumes on Jan 21</figcaption></figure> <stembedurl>https://stocktwits.com/ProphetMargins/message/600715614</stembedurl><stembedurl>https://stocktwits.com/lextrading/message/600704627</stembedurl>Separately, Citi analyst Alicia Yap also placed the company on a "90-day positive catalyst watch" with a ‘Buy’ rating with a $51 price target. The view was based on the continuation of the company’s national trade-in programs for 2025 in major provinces like Hubei, Jiangsu and Hunan, among others, the Fly.com reported.According to the report, JD.com’s early mover positioning in trade-in programs should support potentially stronger-than-expected merchandise volume and revenue growth in the first half of 2025 with upside risks to consensus estimates.JD.com also stood second on a recent Stocktwits poll that asked users to pick large-cap Chinese companies they were most optimistic about. About 18% of commenters picked JD.com that came second to Alibaba Holdings, which scored 60%.<figure class="image image_resized" style="width:77.54%;"><img style="aspect-ratio:1252/690;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_01_21_at_2_05_58_PM_43da92affb.png" alt="Screenshot 2025-01-21 at 2.05.58 PM.png" width="1252" height="690"></figure>&nbsp;<a href="https://stocktwits.com/symbol/JD">JD.com stock </a>is up 12% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com

Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

JD Stock Surges After JP Morgan Puts It On ‘Positive Catalyst Watch': Retail’s Upbeat

Sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ last week.

Chinese e-commerce retailer JD.com, Inc. ($JD) reported Thursday ahead of the market open higher earnings and revenue for the September quarter.Beijing-based JD.com’s quarterly non-GAAP earnings per share (EPS) came in at 8.68 yuan or $1.20, up 29.5% year-over-year (YoY). This exceeded the $1.06 per share consensus, according to Stocktwits data.Net revenue rose 5.1% YoY to 260.4 billion yuan, missing the 261.45-billion-yuan LSEG consensus, according to Reuters.The yuan to USD conversions are based on the current exchange rate.The lackluster top-line performance reflected the domestic economy’s travails amid a struggling property market, moderating growth, and a deflationary environment.&nbsp;The economy and geopolitical risks surrounding&nbsp;President-elect&nbsp;Donald Trump’s victory in the U.S. prompted the central bank and the government to announce copious stimulus measures.JD.com is also left to contend with highly competitive industry dynamics.&nbsp;Sandy Xu, CEO of JD.com, said, “We saw an uptick in our topline growth, as well as healthy profitability in the third quarter, as overall consumer sentiment continued to brighten.”“Our general merchandise category also grew robustly in the quarter, driven by our efforts in driving better user experience and user mindshare, which were also highlighted by the enthusiastic user response to our Singles Day Grand Promotion this year.”CFO Su Shan said the company’s efforts to build up supply chain capabilities in a bid to drive better scale benefits and operating efficiencies helped expand margins during the quarter.&nbsp;As of 9 a.m. ET, JD.com shares fell 0.67% to $35.45.<figure class="image"><a href="https://stocktwits.com/symbol/JD"><img style="aspect-ratio:632/130;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/jd_sentiment_e779abe570.png" alt="jd-sentiment.png" width="632" height="130"></a><figcaption>JD sentiment and message volume November 14, 2024 premarket as of 9:00 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Retail sentiment on Stocktwits improved from ‘bearish’ (37/100) a day ago to ‘bullish’ (63/100), with message volume remaining ‘extremely high’.A user on Stocktwits platform termed the quarter as “great” and hoped that Trump&nbsp;doesn’t crush China.&nbsp;<a href="https://stocktwits.com/walter36/message/592517221">https://stocktwits.com/walter36/message/592517221</a>Another lauded the company’s cash position, profits, and efficiency as well as its attractive valuation.&nbsp;<stembedurl>https://stocktwits.com/NothnSpecial/message/592507540</stembedurl>The yuan trades at 7.24 versus a dollar.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cisco-q1-2025-revenue-eps-fell-but-came-in-ahead-of-consensus/cJ4ZaQ9RfO">Cisco Stock Pulls Back Despite Q1 Beat, In-Line Guidance: Retail Stays Upbeat</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

JD.com said building up supply chain capabilities helped improve margins. 

JD.com Stock Listless Despite Q3 Profit Beat: Retail Is Doubling Down

JD.com’s modest revenue growth came amid a struggling Chinese property market, moderating growth, and a deflationary environment.

Schwab Strategic Trust - Schwab Fundamental Emerging Markets Equity ETF

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Current Price	$40.48
Prev Close	$40.02
Open	$40.30
Dividend Yield	N/A
50-Day Moving Average	$39.04
Beta	N/A
Avg. Volume	1.39M
PE Ratio	N/A

52-Week High	$40.97
52-Week Low	$29.90
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FNDE
Schwab Strategic Trust - Schwab Fundamental Emerging Markets Large Company Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FNDE News

FNDESchwab Strategic Trust - Schwab Fundamental Emerging Markets Large Company Index ETF